Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 16, 2026

Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN
11:50

Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN

Published on: April 3, 2026

Decoding Small Cell Lung Cancer: Molecular Subtypes, Surface Antigens, and the Target-Modality Problem.

Mijail I Zambrano Iglesias1, Daniel Rosas1, Salih Akgun2

  • 1Memorial Cancer Institute, Pembroke Pines, FL 33026, USA.

Cancers
|July 15, 2026
PubMed
Summary

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.

International journal of molecular sciences·2026
Same author

Lung Cancer Disparities in the United States: The Role of Smoking, Comorbidities, Socioeconomic Status, and Regional Variation.

Cureus·2026
Same author

Real-World Survival and Toxicity Outcomes of Fluorouracil With vs. Without Leucovorin in Metastatic Colorectal Cancer.

Journal of gastrointestinal cancer·2026
Same author

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

International journal of molecular sciences·2026
Same author

Creatine Supplementation in Preclinical Models Receiving Immune Checkpoint Inhibitor Therapy: A Systematic Review.

Cureus·2026
Same author

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring <i>EGFR</i> Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy.

International journal of molecular sciences·2026

Small cell lung cancer (SCLC) is now understood through molecular subtypes, impacting treatment. Delivery method, not just target, is key for therapeutic success in SCLC, especially with evolving tumor biology.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Small cell lung cancer (SCLC) was historically viewed as a single aggressive entity.
  • Recent transcriptomic profiling reveals distinct SCLC molecular subtypes (SCLC-A, -N, -P, -I) with unique characteristics.
  • The delta-like ligand 3 (DLL3) target has shown differential success based on therapeutic modality.

Purpose of the Study:

  • To integrate SCLC molecular subtypes and biomarkers with current treatment standards.
  • To propose that delivery modality is a critical factor in SCLC therapeutic success.
  • To analyze the implications for biomarker development and precision oncology in SCLC.

Main Methods:

  • Review of transcriptomic profiling data to define SCLC subtypes.
Keywords:
ASCL1B7-H3DLL3NEUROD1POU2F3bispecific T-cell engagerprecision oncologysmall cell lung cancertarlatamabtranscriptomic subtypes

Related Experiment Videos

Last Updated: Jul 16, 2026

Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&amp;RUN
11:50

Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN

Published on: April 3, 2026

  • Analysis of clinical trial outcomes for DLL3-directed therapies (antibody-drug conjugates vs. bispecific T-cell engagers).
  • Integration of current SCLC treatment regimens (chemoimmunotherapy, maintenance therapy) with molecular subtypes.

    • Main Results:

    • SCLC subtypes exhibit distinct immune microenvironments and therapeutic vulnerabilities.
    • Bispecific T-cell engagers targeting DLL3 demonstrated success, while antibody-drug conjugates failed.
    • Delivery modality influences efficacy, favoring modalities that recruit cell-cycle-independent cytotoxic effectors.

    Conclusions:

    • Therapeutic success in SCLC depends on delivery modality, target biology, and tumor heterogeneity.
    • Understanding SCLC subtypes and tumor plasticity is crucial for precision oncology.
    • Emerging therapies targeting B7-H3 and SEZ6 will further test these frameworks.